Atrial Fibrillation in Indian Women: Diagnosis & Treatment

• AF is an irregular, often fast heartbeat caused by chaotic electrical signals in the heart's upper chambers; it can form clots that travel to the brain and cause stroke.
• Women with AF carry a higher stroke risk than men yet are anticoagulated less often. The CHA2DS2-VASc score adds 1 point for female sex.
• A standard ECG confirms AF only if it is happening during the test; intermittent AF needs a Holter, event monitor or a smartwatch ECG, confirmed on a 12-lead ECG.
• If your stroke risk score is high, a blood thinner (usually a DOAC such as apixaban) is the single most important treatment. Aspirin alone is not enough.
• Controlling blood pressure, weight, diabetes, sleep apnoea, thyroid and alcohol reduces AF episodes and improves treatment success.
• See a doctor urgently for chest pain, severe breathlessness, fainting, or any stroke sign (face droop, arm weakness, slurred speech).

Atrial fibrillation is an abnormal heart rhythm in which the upper chambers of the heart (the atria) fire fast, chaotic electrical signals instead of beating in a steady, coordinated way. The result is an irregular and often rapid heartbeat, a less efficient pump, and pooling of blood in the atria. That pooled blood can form a clot, and if the clot travels to the brain it causes a stroke. AF is the most common sustained arrhythmia, affecting an estimated 2-3% of adults worldwide, and it becomes more common with age.

In India, AF is estimated to affect roughly 0.5-1.5% of adults. The true figure is likely higher because so much AF is silent or missed. One reason AF matters greatly for Indian women is rheumatic heart disease: childhood rheumatic fever can scar the mitral valve, stretch the left atrium and trigger AF. This valve disease remains far more common in India than in the West, and it disproportionately affects women.

AF is grouped by how long it lasts. Paroxysmal AF starts and stops on its own, usually within 48 hours and always within 7 days. Persistent AF lasts more than 7 days and needs treatment to convert. Long-standing persistent AF has been present for over a year, and permanent AF is accepted as the ongoing rhythm. Many people slowly progress from occasional episodes to permanent AF over years.

Symptoms vary enormously. Some people feel nothing at all (silent AF, which is common and still dangerous). Others have palpitations, breathlessness, tiredness, chest discomfort, dizziness or even fainting. In women, AF is often picked up later because the presentation can be quieter, such as fatigue and breathlessness rather than dramatic palpitations. Women also tend to develop AF at an older age, feel more symptomatic when they do, carry a higher stroke risk and are referred for procedures less often. If your main complaint is a pounding or fluttering heart, our guide to heart palpitations during pregnancy and the broader picture of why heart disease looks different in Indian women are useful companions.

A standard 12-lead ECG (around Rs 150-500) is the first test and confirms AF if your heart is in the abnormal rhythm at the moment of recording. On the ECG, doctors look for absent P waves, irregular spacing between beats and a variable rate. It is quick, cheap and available almost everywhere. The catch is that paroxysmal AF may not be present during your clinic visit.

To catch intermittent AF, doctors use ambulatory monitoring. A 24- to 48-hour Holter monitor (around Rs 1,500-4,000) records your ECG continuously, and a 7- or 14-day Holter or event monitor extends that window. An external loop recorder (around Rs 5,000-15,000) records when you press a button or when it detects something abnormal, which suits infrequent symptoms. For difficult cases such as unexplained stroke or fainting, an implantable loop recorder (around Rs 80,000-2 lakh including the procedure) can monitor for up to three years.

Smartwatches and wearables (Apple Watch, Samsung Galaxy Watch, Fitbit, Garmin and others) now offer single-lead ECG features that can flag possible AF with reasonable accuracy. They are a helpful screening tool, but any AF a wearable detects should be confirmed on a formal 12-lead ECG before treatment decisions are made.

Simple screening matters too. Feeling the pulse for irregularity during a routine blood-pressure check is free and effective, especially after age 65. Extended monitoring is also done after a stroke of unknown cause, because 15-20% of these strokes turn out to be driven by AF. An echocardiogram (around Rs 1,500-4,500) is usually arranged to check the heart valves, the size of the left atrium and the pumping function, all of which guide treatment.

AF raises the risk of stroke roughly five-fold, but the actual risk varies hugely from person to person. A young person with no other risk factors has a low risk; an older person with several risk factors has a high one. Doctors use the CHA2DS2-VASc score to estimate your yearly stroke risk and decide whether you need a blood thinner.

The score gives points for: congestive heart failure (1), hypertension (1), age 65-74 (1) or 75 and over (2), diabetes (1), prior stroke, TIA or clot (2), vascular disease such as a previous heart attack or peripheral artery disease (1), and female sex (1).

This female-sex point matters. A 65-year-old woman with high blood pressure scores 3 (1 for age, 1 for hypertension, 1 for being female), which clearly calls for a blood thinner. A man with the same two factors scores 2. The lower treatment threshold for women is not arbitrary; it reflects their genuinely higher stroke risk.

As a rule of thumb, a blood thinner is strongly recommended once the score reaches 2 in men or 3 in women, and is considered through shared decision-making at one point lower. A separate score called HAS-BLED estimates bleeding risk, but a high score is a reason for closer monitoring, not for withholding protection. For most people who need it, the stroke-prevention benefit clearly outweighs the bleeding risk. To understand what a stroke looks like and why fast action saves brain, read our guide to stroke warning signs in Indian women.

If your score says you need stroke protection, an anticoagulant ("blood thinner") is the most important part of treatment. Direct oral anticoagulants (DOACs) are now first choice for most people with non-valvular AF because they have predictable dosing, need no routine blood tests, have fewer food and drug interactions, and carry a lower risk of bleeding into the brain than warfarin. Their downsides are higher cost and a shorter safety margin if you miss a dose.

The DOACs available in India include apixaban (5 mg twice daily, roughly Rs 1,500-4,500 a month), dabigatran (150 mg twice daily), rivaroxaban (20 mg once daily) and edoxaban (60 mg once daily). Doses are reduced in older age, low body weight or reduced kidney function. Apixaban is often preferred in older patients and in chronic kidney disease because of its favourable bleeding profile.

Warfarin (around Rs 50-200 a month) is still essential for some conditions, especially mechanical heart valves and significant rheumatic mitral stenosis, where DOACs are not adequately studied. Warfarin needs regular PT-INR blood tests (target INR usually 2-3) and works well only if you stay in the target range most of the time. Diet, other medicines and access to testing make this harder for many Indian patients, so the choice between warfarin and a DOAC is made with your cardiologist.

A few practical points. If you miss a DOAC dose, take it as soon as you remember within about 6 hours (once-daily) or 12 hours (twice-daily); otherwise skip it and resume normally. Before surgery, DOACs are usually paused for 1-3 days depending on the bleeding risk. Crucially, aspirin alone is not adequate stroke prevention for AF. If a blood thinner is indicated, aspirin is not a substitute. Anyone on a blood thinner should also know the signs of an abnormal clot such as a deep vein thrombosis.

Once stroke risk is covered, the next decision is whether to let the AF continue while keeping the heart rate in check (rate control) or to try to restore and hold a normal rhythm (rhythm control). For years these were considered roughly equal for most people. More recent evidence suggests that restoring rhythm early, soon after diagnosis, can improve outcomes for some patients, particularly younger people and those with troublesome symptoms.

Rate control aims to keep the resting heart rate below about 110 beats per minute, or stricter if symptoms persist. The mainstays are beta-blockers (such as metoprolol or bisoprolol), with non-dihydropyridine calcium-channel blockers (diltiazem or verapamil) as an alternative, and digoxin occasionally added, mainly in heart failure. Most people need one or two of these.

Rhythm control uses anti-arrhythmic drugs to keep the heart in normal rhythm. Amiodarone is the most effective but needs monitoring of the thyroid, lungs, liver and eyes; flecainide and propafenone suit people with structurally normal hearts; sotalol and dronedarone are other options. Because amiodarone can affect the thyroid, doctors check thyroid function, and untreated Hypothyroidism in Indian Women: Diagnosis, Treatment & Pregnancy or an overactive thyroid should be sorted out as part of care.

Cardioversion can reset the rhythm, either electrically (a brief, synchronised shock under sedation) or with medication. It restores normal rhythm in most people initially, but AF often returns within a year without maintenance treatment. Importantly, anticoagulation must continue for at least 4 weeks after a cardioversion, and usually long-term if your stroke score warrants it.

Catheter ablation has become a highly effective option for symptomatic AF, especially paroxysmal or early persistent AF that medicines do not control well. Thin catheters are guided from a vein in the groin to the heart, where the areas that trigger AF (mostly around the pulmonary veins) are electrically isolated using heat, freezing or, more recently, pulsed-field energy that targets heart tissue more selectively.

Ablation is most useful for symptomatic paroxysmal or early persistent AF, for people who prefer a rhythm-control strategy, and for selected patients with AF and heart failure. It is less effective when AF has been present for a long time or when the left atrium is very enlarged. Freedom from AF at one year is roughly 60-80% for paroxysmal AF and 50-70% for persistent AF, and a second procedure is sometimes needed.

The procedure usually takes 2-4 hours under sedation or general anaesthesia, with a 1-2 day hospital stay and 1-2 weeks of recovery. Serious complications such as bleeding around the heart or stroke occur in under 1%. In India in 2026, ablation typically costs around Rs 2-5 lakh at major centres.

For people who genuinely cannot take long-term anticoagulation, left atrial appendage closure (devices such as WATCHMAN or Amulet, around Rs 4-8 lakh) seals off the pouch where most AF clots form. AF surgery (the Maze procedure) is often done at the same time as valve surgery. Electrophysiology expertise is available at centres such as AIIMS Delhi, Asian Heart Institute Mumbai, Medanta Gurugram, Fortis Escorts Delhi, Narayana Health Bengaluru, CMC Vellore, KEM Mumbai, SGPGI Lucknow, Madras Medical Mission and Apollo and Manipal hospitals.

AF in pregnancy is uncommon but increasingly recognised. It usually arises in women who already have structural heart disease, especially rheumatic mitral valve disease, which remains common in Indian women. Other triggers include the normal increase in blood volume and heart workload during pregnancy, an overactive thyroid and peripartum cardiomyopathy. Pregnancy raises AF risk in women with heart disease, which is why a cardiology review before conceiving is so valuable.

If you have AF or heart disease and are planning a pregnancy, pre-pregnancy planning should assess the cause and severity, optimise rate or rhythm, review every medicine for safety, plan anticoagulation and arrange high-risk obstetric care. Women with a mechanical heart valve and AF have especially complex anticoagulation needs.

Anticoagulation choices change in pregnancy. Warfarin can harm the fetus, particularly in the first trimester, and is generally avoided except in specific mechanical-valve situations. Low molecular weight heparin (such as enoxaparin) is preferred for most women because it does not cross the placenta. DOACs are not recommended in pregnancy because of limited safety data, so women on a DOAC are usually switched before conceiving.

For controlling the heart in pregnancy, beta-blockers such as metoprolol and labetalol are preferred (atenolol is avoided), and certain calcium-channel blockers are acceptable. Amiodarone is generally avoided. Electrical cardioversion is considered safe with fetal monitoring, and ablation is usually postponed until after delivery. Cardio-obstetric expertise is available at AIIMS Delhi, CMC Vellore, KEM Mumbai, JIPMER, SCTIMST Trivandrum and major Apollo, Fortis, Manipal and Medanta centres. A fetal echocardiogram may be advised when the mother has heart disease.

AF often reflects other heart and metabolic problems, and treating these reduces both episodes and progression. Blood pressure is central: aiming for below 130/80 and keeping it there lowers AF and improves the success of ablation, while poorly controlled pressure roughly doubles the chance AF returns. Our detailed guide to hypertension in Indian women walks through targets and medicines.

Weight matters enormously. Losing around 10% of body weight can substantially cut AF burden in people with obesity and sometimes reduces the need for ablation. Obstructive sleep apnoea is another big driver: untreated, it causes AF to return in many people after ablation, while CPAP treatment greatly improves control. If you snore, wake unrefreshed or have been told you stop breathing in your sleep, read about sleep apnoea risk after menopause.

Diabetes should be managed well, ideally with heart-protective medicines; see type 2 diabetes in Indian women. Thyroid disease is a reversible cause, so doctors check TSH at diagnosis and treat any imbalance. Heavy alcohol use is a clear AF trigger, and cutting back helps. Moderate, regular activity protects the heart, although extreme endurance training can paradoxically raise AF risk. Strength training is a safe, valuable part of a heart-healthy routine across the life stages.

Put together, a structured plan of weight loss, blood-pressure and diabetes control, sleep-apnoea treatment, thyroid normalisation, alcohol moderation, stopping smoking, better sleep and steady exercise meaningfully reduces AF and improves quality of life. Many Indian hospitals now run dedicated AF clinics that bring these threads together.

Stroke is the most feared complication of AF and the main reason anticoagulation matters; treatment reduces this risk by 60-70%. Knowing the warning signs of stroke and acting fast can be the difference between full recovery and lasting disability.

Heart failure is the next big concern. AF reduces the heart's output by removing the atria's coordinated "top-up" of each beat, and a persistently fast rate can weaken the heart muscle over months. Conversely, heart failure can itself trigger AF. Good rate or rhythm control alongside standard heart-failure medicines addresses both directions of this relationship.

AF is also linked to a higher risk of memory problems and dementia, largely through small, silent strokes; anticoagulation and good vascular care help reduce this. Beyond these, AF commonly brings tiredness, reduced exercise tolerance, anxiety and low mood from the uncertainty and symptoms.

Living well with AF means treating all of these dimensions: preventing stroke, controlling the rate or rhythm, tackling the underlying risk factors, looking after mental health and understanding your own condition. Trusted patient resources include the Indian Heart Rhythm Society (ihrs.org.in) and the Cardiological Society of India (csi.org.in).

Diagnostic costs in 2026 are broadly: a 12-lead ECG Rs 150-500; a 24-hour Holter Rs 1,500-4,000; a 7-day Holter Rs 3,000-8,000; an external loop recorder Rs 5,000-15,000; an implantable loop recorder with procedure Rs 80,000-2 lakh; an echocardiogram Rs 1,500-4,500; a transoesophageal echo (used before cardioversion to exclude a clot) Rs 5,000-15,000; and thyroid and basic cardiac labs from a few hundred to a few thousand rupees.

Monthly medicine costs are modest for older drugs and higher for newer ones: beta-blockers and calcium-channel blockers Rs 100-400; warfarin Rs 50-200 plus PT-INR tests at Rs 200-500 each (12-24 a year); amiodarone Rs 200-600 plus periodic monitoring; and DOACs Rs 1,500-4,500. Procedures range from cardioversion (Rs 15,000-50,000) to ablation (Rs 2-5 lakh) and left atrial appendage closure (Rs 4-8 lakh).

Financial support is available. Ayushman Bharat PMJAY covers AF diagnosis and treatment, including ablation, up to Rs 5 lakh per family per year at empanelled hospitals. CGHS, ECHS and ESI cover eligible government employees, ex-servicemen and ESI beneficiaries, and several state schemes (Tamil Nadu CMCHIS, Telangana and Andhra Pradesh Aarogyasri, Kerala KASP, Karnataka Arogya Karnataka) help further. Jan Aushadhi pharmacies stock many cardiovascular medicines at a substantial discount.

Centres with strong electrophysiology services include AIIMS Delhi, Asian Heart Institute Mumbai, Medanta Gurugram, Fortis Escorts Delhi, Narayana Health Bengaluru, the Apollo and Manipal chains, CMC Vellore, KEM Mumbai, SGPGI Lucknow and Madras Medical Mission Chennai. The Indian Heart Rhythm Society and the Cardiological Society of India maintain specialist directories.

Call an ambulance (102 or 108) or go straight to the nearest emergency department if you have:

Make an appointment with your doctor or cardiologist (without an emergency) if you have:

• World Health Organization — Cardiovascular diseases (CVDs))
• NHS — Atrial fibrillation
• American Heart Association — What is Atrial Fibrillation (AFib or AF)?
• 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation (Circulation)
• 2024 ESC Guidelines for the management of atrial fibrillation (European Heart Journal)
• Cardiological Society of India
• Indian Heart Rhythm Society